Incidence and Timing of Venous Thromboembolism in Patients With Advanced Endometrial Cancer

Patients with advanced endometrial cancer (EC) are at risk for venous thromboembolism (VTE), though risk by treatment phase remains unclear. This single-institution retrospective study evaluated 84 patients receiving neoadjuvant chemotherapy (NACT, n=34) or adjuvant chemotherapy (n=50) for stage III–IV EC. Overall VTE incidence was 27.4% (95% CI, 18.8–38.0%). Among patients receiving NACT, VTE occurred in 14.3% during NACT and in 16.7% during ongoing chemotherapy. Postoperative and adjuvant treatment rates were less than 10.0%. Khorana score was a poor predictor of VTE, with 52.0% of intermediate-risk patients developing VTE. These findings highlight the need for improved VTE risk-reduction strategies, including larger studies to evaluate optimization of risk stratification and VTE prophylaxis during systemic therapy for advanced EC.